First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022· Net sales amounted to SEK 0 million (SEK 0.0 million).· R&D costs amounted to SEK 10,6 million (8,2 million).· Operating...
Read MoreThe year in brief October – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (0,0 million). R&D costs amounted to SEK 12,9 million (11,2 million). Operating profit for the fourth quarter amounted to SEK...
Read MoreKancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.
Read MoreThis is a translation of press release in Swedish (2021-11-22). Kancera AB (Nasdaq First North Premier Growth Market: KAN) today presents preclinical results that show that KAND145 effectively reduces tumor size in a disease model of ovarian cancer. These...
Read MoreThis is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with KAND567 in patients with COVID-19. The randomized double-blinded study...
Read MoreThe year in brief Juli – SeptemberFinancial summary of the third quarter Net sales amounted to SEK 0 million (0,05 million). R&D costs amounted to SEK 10,9 million (8,8 million). Operating profit for the third quarter amounted to SEK...
Read MoreSecond quarter in brief as well as the period 1 January to 30 June 2021 Net sales for the period (January to June) amounted to SEK 0 million (SEK 0 million), of which the second quarter contributed SEK 0 million...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent of the originally planned number of COVID-19 patients have...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the...
Read MoreFirst quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...
Read More